Kelley Lauren Coffman, MD, on the Next Steps for a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs

Video
Conference|ASCO Gastrointestinal Cancer Symposium

The hospitalist at Memorial Sloan Kettering Cancer Center spoke about the next steps for a study which evaluated patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE.

Study findings presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium revealed that investigators saw a meaningful disease control rate among patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE (Lutathera).

In an interview with CancerNetwork®, Kelley Lauren Coffman, MD, a hospitalist at Memorial Sloan Kettering Cancer Center, explained what she believes are the next steps for this research.

Transcription:

Our group has a particular interest in identifying genetic or biomarkers that might help beforehand to predict a patient’s response to therapy. Even in our study [and] in our review of these patients, we looked at the last 2 years. We had access to genetic sequencing, and about two-thirds of the tumors [by] a basic genetic review [demonstrated] mutations…similar to what we expected for well-differentiated tumor types. In the future, going forward, we’d really like to see if there’s a way to identify either genetic or biomarkers that might predict response or resistance to this therapy so that beforehand, you could really identify which patients are going to benefit without subjecting them to the toxicities.

Related Videos
Administering immunotherapy following surgery in patients with early-stage triple-negative breast cancer does not appear to be as effective as beginning with neoadjuvant treatment, says Peter Schmid, MD, PhD.
Heather A. Parsons, MD, MPH, says she is excited about HER2 as a biomarker and investigating the biology of metastatic breast cancer with a minimally invasive liquid biopsy platform.
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Related Content
All dose-limiting toxicities with SIM0270 in a phase 1 trial appear to be manageable with dose reductions in those with estrogen receptor–positive, HER2-negative breast cancer.

Novel SERD Yields Favorable Safety in ER+/HER2– Advanced Breast Cancer

December 8th 2023
Article

All dose-limiting toxicities with SIM0270 in a phase 1 trial appear to be manageable with dose reductions in those with estrogen receptor–positive, HER2-negative breast cancer.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Future research may focus on the relationship between neoadjuvant chemotherapy regimens, pathologic complete response, and whole transcriptome changes in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.

Profiling Tests May Predict Chemo Efficacy in Early-Stage Breast Cancer

December 8th 2023
Article

Future research may focus on the relationship between neoadjuvant chemotherapy regimens, pathologic complete response, and whole transcriptome changes in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.

Experts from UCLA Health discuss key data presented at The Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer and how they may apply to clinical practice.

Oncology On-The-Go Podcast: SGO 2023 Recap

April 24th 2023
Podcast

Experts from UCLA Health discuss key data presented at The Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer and how they may apply to clinical practice.

Safety findings in the phase 1b DESTINY-Breast08 are comparable with prior reports of trastuzumab deruxtecan and endocrine therapy in HER2-low hormone receptor–positive metastatic breast cancer.

T-DXd Combo Shows Encouraging Activity in HER2-Low/HR+ Breast Cancer

December 8th 2023
Article

Safety findings in the phase 1b DESTINY-Breast08 are comparable with prior reports of trastuzumab deruxtecan and endocrine therapy in HER2-low hormone receptor–positive metastatic breast cancer.

Data from the phase 3 TROPION-Breast01 trial support datopotamab deruxtecan as a potential treatment option for patients with endocrine-resistant, hormone receptor–positive, metastatic breast cancer, says Aditya Bardia, MD, MPH.

Dato-DXd Improves PFS Vs Chemo in HR+/HER2– Metastatic Breast Cancer

December 8th 2023
Article

Data from the phase 3 TROPION-Breast01 trial support datopotamab deruxtecan as a potential treatment option for patients with endocrine-resistant, hormone receptor–positive, metastatic breast cancer, says Aditya Bardia, MD, MPH.